Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 61 out of 100. Prevention trials

Topic: Risk, prevention and care in population studies

Plain-language summary

The global metabolic disorder, type 2 diabetes mellitus (T2DM), significantly increases the risk of cognitive dysfunction, including Alzheimer's disease (AD) and mild cognitive impairment (MCI). The aim is to inform therapeutic strategies that could delay or prevent cognitive decline associated with T2DM.Additionally, it analyzes the potential challenges related to implementing the MedDiet in the context of T2DM-associated cognitive impairment.Peripheral insulin resistance (IR) in T2DM disrupts central insulin signaling through various mechanisms, leading to neurodegeneration. Neuroimaging studies have shown that the utilization rate of glucose in the brain of patients with T2DM is reduced and the hippocampus is atrophied (15) , which correlates with impairments in memory and executive function. These findings highlight that peripheral insulin resistance plays an important role in the dysfunction of brain insulin signaling and AD like changes in T2DM.Dyslipidemia, also known as lipid metabolism disorders, involves imbalances in cholesterol, triglycerides, and other lipid components. The metabolic stress associated with T2DM impairs ApoE mediated clearance of Aβ, which synergizes with the intrinsic clearance deficiency of ApoE4 to accelerate the accumulation of Aβ. Microvascular complications, including diabetic retinopathy (a marker of cerebral microvascular injury), are strongly associated with more severe cognitive decline (23) . Research has shown that extensive microvascular damage can affect synaptic plasticity and neuronal metabolism (24) . Additionally, chronic hyperglycemia-induced endothelial dysfunction weakens BBB, increasing the risk of cerebral edema, hemorrhage, and the accumulation of neurotoxic substances such as β-amyloid, which further exacerbates neuronal damage.Beyond microvascular injury, large-vessel atherosclerosis, such as carotid artery stenosis, significantly impacts cognitive networks by altering cerebral hemodynamics. Studies have shown that the severity of carotid stenosis in patients with T2DM correlates with the extent of cognitive impairment, with severe stenosis doubling the risk of cognitive decline (25) . In response, he conducted the renowned "Seven Countries Study," which confirmed that the Mediterranean dietary pattern was associated with a lower risk of cardiovascular events (32,33) . It is hypothesized that such effects may contribute to a reduction in the risk of dementia (34)(35)(36) .Building on his research, the

What this study adds

Evidence grade: High

This is a pooled review of 250,000 participants. This review examines how type 2 diabetes may increase risk of cognitive dysfunction including Alzheimer's disease and discusses the Mediterranean diet as a possible strategy. Reported effect size: HR=0.60; or 11.4.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Zheng, C., Zhang, Q., Liu, F., & Qiu, G. (2025). The role of the Mediterranean diet in the treatment of cognitive dysfunction in patients with type 2 diabetes mellitus. Frontiers in Nutrition. https://doi.org/10.3389/fnut.2025.1654684

Vancouver

Zheng C, Zhang Q, Liu F, Qiu G. The role of the Mediterranean diet in the treatment of cognitive dysfunction in patients with type 2 diabetes mellitus. Frontiers in Nutrition. 2025. doi:10.3389/fnut.2025.1654684. PMID: 40896190.

BibTeX

@article{zheng2025-40896190,
  author  = {Zheng, Chunyan and Zhang, Qinqin and Liu, Fengli and Qiu, Guihong},
  title   = {{The role of the Mediterranean diet in the treatment of cognitive dysfunction in patients with type 2 diabetes mellitus}},
  journal = {Frontiers in Nutrition},
  year    = {2025},
  doi     = {10.3389/fnut.2025.1654684},
  pmid    = {40896190},
  url     = {https://doi.org/10.3389/fnut.2025.1654684}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This review examines how type 2 diabetes may increase risk of cognitive dysfunction including Alzheimer's disease and discusses the Mediterranean diet as a possible strategy. It does not provide evidence that the diet treats or prevents Alzheimer's disease.

Study details

How this study scored 61/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 1 of 4; Study design 12 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 4 of 4; Effect reported 3 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 1 of 7; Citations per year 1 of 5; Impact for its field and year 3 of 6; Cited by studies here 0 of 6; Still being cited 1 of 4; Senior author's track record left out, no data; Institution's track record 0 of 3; Multicenter collaboration 0 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. 59 of the 96 points it could be judged on, which is 61 of 100. Total 61 of 100.59 of the 96 points we could judge = 61 of 100

Published in a peer-reviewed journal, and it is a meta-analysis pooling many studies. We have no data on senior author's track record, so that was left out: it earned 59 of the 96 points we could judge it on, which is 61 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Frontiers in Nutrition)
Journal's citation record 1 / 4 Frontiers in Nutrition: journal h-index 147 (OpenAlex, 2026-10-29)
Study design 12 / 12 A meta-analysis pooling many studies
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 4 / 4 250,000 participants
Effect reported 3 / 3 Effect reported with a statistic (interval, p-value, ratio or similar)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 A review of other studies — randomization is not credited here
Times cited 1 / 7 Cited 4 times (OpenAlex, 2026-10-10)
Citations per year 1 / 5 1.3 citations a year over 3 year(s) since 2025
Impact for its field and year 3 / 6 Cited 3.4× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 1 / 4 Cited 4 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record 0 / 3 Central Hospital of Zibo: institution h-index 87 (OpenAlex)
Multicenter collaboration 0 / 3 OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 40896190)
Free to read 2 / 2 Free to read
Points 59 / 96 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 59 of the 96 points we could judge it on is 61 out of 100.
Total 61 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Prevention trials from nearby years

Also tagged “decline”

1,116 studies in the library carry the topic tag “decline”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,116 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Prevention trials

See all studies in Prevention trials →